We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Affimed Nv
10 own
19 watching
Current Price
$0
$0
(0.39%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
189.66M
52-Week High
5.1
52-Week Low
1.03
Average Volume
0.21M
Dividend Yield
--
P/E Ratio
--
Market Capitalization189.66M52-Week High5.152-Week Low1.03Average Volume0.21MDividend Yield--P/E Ratio--What does the Affimed Nv do?
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.
Read More
News & Events about Affimed Nv.
Globe Newswire
1month ago
AFM28 monotherapy receives authorization of a Clinical Trial Application (CTA) for the phase 1 study by the French National Agency for the Safety of Medicines and Health Products (ANSM)Initiation of AFM28 clinical development in the first half of 2023 on track HEIDELBERG, Germany, Dec. 22, 2022 (...
Globe Newswire
1month ago
AFM28 efficiently directs allogeneic NK cells to CD123-positive leukemic cells, including leukemic stem and progenitor cells, inducing their depletion in samples of patients with Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)Leukemia cell lysis was independent of differences in ...
Globe Newswire
2 months ago
Comprehensive correlative science findings from patients treated with AFM24 monotherapy indicate an activation of NK cells and their migration to the tumorInitial signs of clinical activity and a well-managed safety profile with no dose-limiting toxicities were shown in preliminary data from the ...
Globe Newswire
2 months ago
Companies to combine their clinical programs (AFM13, AB-101) to address high unmet need of CD30-positive lymphoma patientsAffimeds AFM13 in combination with cord blood-derived NK cells demonstrated exceptionally high response rates in relapsed and refractory CD30-positive lymphoma patientsAB-101 is ...
Globe Newswire
2 months ago
In 24 patients with CD30-positive lymphoma treated at the highest dose level, the combination treatment of AFM13 with allogeneic NK cells continues to achieve a 100% overall response rate and an improved 70.8% complete response rate Patients received up to four cycles and the treatment was very well...
Frequently Asked Questions
Frequently Asked Questions
What is Affimed Nv share price today?
Can Indians buy Affimed Nv shares?
How can I buy Affimed Nv shares from India?
Can Fractional shares of Affimed Nv be purchased?
What are the documents required to start investing in Affimed Nv stocks?
What is today’s traded volume of Affimed Nv?
What is today’s market capitalisation of Affimed Nv?
What is the 52-Week High and Low Range of Affimed Nv?
What percentage is Affimed Nv down from its 52-Week High?
What percentage is Affimed Nv up from its 52-Week Low?
Current Price
$0
$0
(0.39%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.